206 related articles for article (PubMed ID: 32967726)
1. Electrolytes supplementation can decrease the risk of nephrotoxicity in patients with solid tumors undergoing chemotherapy with cisplatin.
Minzi OMS; Lyimo TE; Furia FF; Marealle AI; Kilonzi M; Bwire GM; Malichewe C
BMC Pharmacol Toxicol; 2020 Sep; 21(1):69. PubMed ID: 32967726
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin Nephrotoxicity and Longitudinal Growth in Children With Solid Tumors: A Retrospective Cohort Study.
Jiménez-Triana CA; Castelán-Martínez OD; Rivas-Ruiz R; Jiménez-Méndez R; Medina A; Clark P; Rassekh R; Castañeda-Hernández G; Carleton B; Medeiros M;
Medicine (Baltimore); 2015 Aug; 94(34):e1413. PubMed ID: 26313789
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.
Kidera Y; Kawakami H; Sakiyama T; Okamoto K; Tanaka K; Takeda M; Kaneda H; Nishina S; Tsurutani J; Fujiwara K; Nomura M; Yamazoe Y; Chiba Y; Nishida S; Tamura T; Nakagawa K
PLoS One; 2014; 9(7):e101902. PubMed ID: 25020203
[TBL] [Abstract][Full Text] [Related]
4. Lower blood pressure and risk of cisplatin nephrotoxicity: a retrospective cohort study.
Komaki K; Kusaba T; Tanaka M; Kado H; Shiotsu Y; Matsui M; Shiozaki A; Nakano H; Ishikawa T; Fujiwara H; Konishi H; Itoh Y; Matoba S; Tamagaki K
BMC Cancer; 2017 Feb; 17(1):144. PubMed ID: 28219368
[TBL] [Abstract][Full Text] [Related]
5. Short hydration with 20 mEq of magnesium supplementation for lung cancer patients receiving cisplatin-based chemotherapy: a prospective study.
Hase T; Miyazaki M; Ichikawa K; Yogo N; Ozawa N; Hatta T; Ando M; Sato M; Kondo M; Yamada K; Hasegawa Y
Int J Clin Oncol; 2020 Nov; 25(11):1928-1935. PubMed ID: 32740717
[TBL] [Abstract][Full Text] [Related]
6. Kidney-protective Effect of Magnesium Supplementation in Cisplatin-containing Chemotherapy for Pediatric Cancer: A Retrospective Study.
Matsui M; Saito Y; Yamaoka S; Yokokawa Y; Morikawa Y; Makimoto A; Yuza Y
J Pediatr Hematol Oncol; 2018 Jul; 40(5):379-381. PubMed ID: 29683958
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors for Cisplatin-Induced Nephrotoxicity: A Multicenter Retrospective Study.
Miyoshi T; Uoi M; Omura F; Tsumagari K; Maesaki S; Yokota C
Oncology; 2021; 99(2):105-113. PubMed ID: 32966986
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Intravenous Mannitol Combined With Normal Saline in Preventing Cisplatin-Induced Nephrotoxicity: A Randomized, Double-Blind, Placebo-Controlled Trial.
Sainamthip P; Saichaemchan S; Satirapoj B; Prasongsook N
JCO Glob Oncol; 2022 Mar; 8():e2100275. PubMed ID: 35436142
[TBL] [Abstract][Full Text] [Related]
9. Hydration with 15 mEq Magnesium Is Effective at Reducingthe Risk for Cisplatin-induced Nephrotoxicity in Patients Receiving Cisplatin (≥50 mg/m2) Combination Chemotherapy.
Yamamoto Y; Watanabe K; Tsukiyama I; Yabushita H; Matsuura K; Wakatsuki A
Anticancer Res; 2016 Apr; 36(4):1873-7. PubMed ID: 27069173
[TBL] [Abstract][Full Text] [Related]
10. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial.
Santoso JT; Lucci JA; Coleman RL; Schafer I; Hannigan EV
Cancer Chemother Pharmacol; 2003 Jul; 52(1):13-8. PubMed ID: 12719883
[TBL] [Abstract][Full Text] [Related]
11. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
12. Science behind cisplatin-induced nephrotoxicity in humans: a clinical study.
Arunkumar PA; Viswanatha GL; Radheshyam N; Mukund H; Belliyappa MS
Asian Pac J Trop Biomed; 2012 Aug; 2(8):640-4. PubMed ID: 23569986
[TBL] [Abstract][Full Text] [Related]
13. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
14. Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy.
McKibbin T; Cheng LL; Kim S; Steuer CE; Owonikoko TK; Khuri FR; Shin DM; Saba NF
Support Care Cancer; 2016 Apr; 24(4):1789-93. PubMed ID: 26446698
[TBL] [Abstract][Full Text] [Related]
15. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods.
Stewart DJ; Dulberg CS; Mikhael NZ; Redmond MD; Montpetit VA; Goel R
Cancer Chemother Pharmacol; 1997; 40(4):293-308. PubMed ID: 9225947
[TBL] [Abstract][Full Text] [Related]
16. Magnesium supplementation therapy to prevent cisplatin-induced acute nephrotoxicity in pediatric cancer: a randomized phase-2 trial.
Matsui M; Makimoto A; Chin M; Koh K; Tomotsune M; Kaneko T; Morikawa Y; Hamada R; Yuza Y
Int J Clin Oncol; 2024 May; 29(5):629-637. PubMed ID: 38564107
[TBL] [Abstract][Full Text] [Related]
17. Changes in the serum, liver, and renal cortical lipids and electrolytes in rabbits with cisplatin-induced nephrotoxicity.
Abdel-Gayoum AA; Ahmida MHS
Turk J Med Sci; 2017 Jun; 47(3):1019-1027. PubMed ID: 28618760
[TBL] [Abstract][Full Text] [Related]
18. Incidence of cisplatin-induced nephrotoxicity and associated factors among cancer patients in Indonesia.
Prasaja Y; Sutandyo N; Andrajati R
Asian Pac J Cancer Prev; 2015; 16(3):1117-22. PubMed ID: 25735341
[TBL] [Abstract][Full Text] [Related]
19. Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study).
Suppadungsuk S; Phitakwatchara W; Reungwetwattana T; Pathumarak A; Phakdeekitcharoen B; Kitiyakara C; Srisuwarn P; Davenport A; Nongnuch A
ESMO Open; 2022 Feb; 7(1):100351. PubMed ID: 34953401
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study.
Yoshida T; Niho S; Toda M; Goto K; Yoh K; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Apr; 44(4):346-54. PubMed ID: 24503028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]